Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for preventive treatment of chronic migraine (2 dose regimens vs placebo)
2015-004549-23Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in chronic migraine (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change in monthly average number of headache days of at least moderate severity. Started May 2016; status: completed.
02
Drugs
fremanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2015-004549-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004549-23.